Newsfile Corp
16 Jul 2026, 13:48 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
GRAIL's NHS-Galleri Trial failed to achieve a statistically significant reduction in late-stage cancers. — Failure of a lead product's primary clinical endpoint is a fundamental blow to the company's core value proposition and future revenue potential.
-0.90Berger Montague has filed a class action lawsuit against GRAIL alleging the company concealed inadequacies in the NHS-Galleri trial design. — Securities fraud litigation creates additional financial liabilities and suggests potential governance or transparency issues.
-0.40Which stocks this story touches
The company is facing a class action lawsuit following the failure of its NHS-Galleri trial and a subsequent 50% drop in stock price.
Continue reading
6 related stories
Search tags
Mentioned in the context of an investor alert regarding a legal deadline, implying potential litigation.
Mentioned in a notice encouraging investors to inquire about a securities fraud class action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
16h ago
